Smith & Nephew plc Q2 & H1 2024 Results Announced

TL;DR

Smith & Nephew dropped Q2/H1 2024 results Aug 1st. Check the press release for numbers.

AI Summary

Smith & Nephew plc announced its Second Quarter and First Half 2024 results on August 1, 2024. The company is a foreign private issuer filing a Form 6-K with the SEC. Specific financial details for the quarter and half-year are not provided in this document, which primarily serves as a cover for a press release.

Why It Matters

This filing provides investors with the latest financial performance update for Smith & Nephew plc, crucial for assessing the company's trajectory and making investment decisions.

Risk Assessment

Risk Level: low — This is a routine financial results announcement from a publicly traded company, not indicating any unusual risks.

Key Players & Entities

• SMITH & NEPHEW PLC (company) — Registrant
• 001-14978 (company) — SEC File Number
• August 1, 2024 (date) — Filing Date and Press Release Date

FAQ

Key Financial Figures

• $1,441 million — Trading Highlights 1,2 Q2 revenue of $1,441 million (Q2 2023: $1,379 million), up 5.6% (4.6
• $1,379 million — Q2 revenue of $1,441 million (Q2 2023: $1,379 million), up 5.6% (4.6% on a reported basis inc
• $2,827 million — ing H1 Highlights 1,2 H1 revenue of $2,827 million (H1 2023: $2,734 million), up 4.3% (3.4
• $2,734 million — H1 revenue of $2,827 million (H1 2023: $2,734 million), up 4.3% (3.4% on a reported basis inc
• $328 million — 90bps FX headwind) Operating profit of $328 million (H1 2023: $275 million), up 19.5% repor
• $275 million — rating profit of $328 million (H1 2023: $275 million), up 19.5% reported Trading profit up
• $471 million — 5% reported Trading profit up 12.8% to $471 million (H1 2023: $417 million) Trading profit
• $417 million — ofit up 12.8% to $471 million (H1 2023: $417 million) Trading profit margin expansion to 16
• $368 million — enefits Cash generated from operations $368 million (H1 2023: $215 million) Significant im
• $215 million — from operations $368 million (H1 2023: $215 million) Significant improvement in trading ca
• $284 million — 3: 26%), trading cash flow increased to $284 million (H1 2023: $110 million) Adjusted earni
• $110 million — low increased to $284 million (H1 2023: $110 million) Adjusted earnings per share (EPSA') u
• $200 million — ng opportunities. Including the initial $200 million of 12-Point Plan savings announced in 2
• $325 million — al saving opportunities are now between $325 million and $375 million, phased from 2023 thro
• $375 m — nities are now between $325 million and $375 million, phased from 2023 through to 2027

Filing Documents

• tmb-20240801x6k.htm (6-K) — 1186KB
• tmb-20240801x6k001.jpg (GRAPHIC) — 5KB
• 0001558370-24-010519.txt ( ) — 1194KB

Press release entitled " Smith+Nephew Second Quarter and First Half 2024 Results ", dated August 1, 2024

Item 1. Press release entitled " Smith+Nephew Second Quarter and First Half 2024 Results ", dated August 1, 2024.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Smith & Nephew plc (Registrant) Date: August 1, 2024 By: /s/ Helen Barraclough Helen Barraclough Company Secretary Smith+Nephew Second Quarter and First Half 2024 Results 12-Point Plan driving first half revenue growth, trading margin expansion and stronger cash flow. Full year guidance unchanged 1 August 2024 Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, reports results for the second quarter and first half ended 29 June 2024: 29 June 1 July Reported Underlying 2024 2023 growth growth $m $m % % Second Quarter Results 1,2 Revenue 1,441 1,379 4.6 5.6 Half Year Results 1,2 Revenue 2,827 2,734 3.4 4.3 Operating profit 328 275 19.5 Operating profit margin (%) 11.6 10.0 EPS (cents) 24.5 19.7 24.6 Trading profit 471 417 12.8 Trading profit margin (%) 16.7 15.3 EPSA (cents) 37.6 34.9 7.7 Q2 Trading Highlights 1,2 Q2 revenue of $1,441 million (Q2 2023: $1,379 million), up 5.6% (4.6% on a reported basis including -100bps FX headwind) Orthopaedics revenue up 5.8% (4.9% reported), with good growth across Hip and Knee Implants outside the US, Other Reconstruction and Trauma & Extremities; further progress in addressing performance in US Hip and Knee Implants Sports Medicine & ENT up 7.6% (6.3% reported), with strong growth across all segments; continued headwind from China sports medicine VBP Advanced Wound Management up 3.3% (2.3% reported), returning to growth with all segments contributing H1 Highlights 1,2 H1 revenue of $2,827 million (H1 2023: $2,734 million), up 4.3% (3.4% on a reported basis including -90bps FX headwind) Operating profit of $328 million (H1 2023: $275 million), up 19.5% reported Trading profit up 12.8% to $471 million (H1 2023: $417

View Full Filing

View this 6-K filing on SEC EDGAR